Skip to main content

Table 1 Clinical results at 1 year in major randomized trials with coronary stenting

From: Long-term outcome after coronary stenting

  

Angiographic restenosis

     

Study/Procedure

n

rate (%)

Death (%)

MI (%)

CABG (%)

PTCA (%)

MACE (%)

BENESTENT [13,17]

       

   Stent

259

22*

1.2

3.5

6.9

10.0*

23.2*

   PTCA

257

32

0.8

1.9

5.1

20.6

31.5

STRESS [14,38]

       

   Stent

205

32*

1.5

3.4

5.8

15.1

21.0

   PTCA

202

42

2.0

3.5

8.9

16.4

26.2

BENESTENT II [35]

       

   Stent (heparin coated)

413

16*

1.0

1.9

1.9

9.4*

15.7*

   PTCA

410

31

1.0

1.5

1.5

15.6

22.4

EPISTENT [11]

       

   Stent + abciximab

794

31†

1.0

4.4

5.8

13.6*

18.6*

   PTCA + abciximab

796

40

2.1

6.4

6.3

18.3

24.9

ARTS [39]

       

   Stent

600

N/A

2.5

5.3

4.7*

12.2*

26.3*

   CABG

605

N/A

2.8

4.0

0.5

3.0

12.2

  1. Study acronyms are defined in the text. *P < 0.05 for the comparison between stent and respective control arm (PTCA or CABG). †Restenosis data presented at the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, 1999. MACE, any major adverse clinical event; MI, myocardial infarction (defined as either Q-wave infarction or creatine kinase elevation ≥ 5 times the upper normal limit); N/A, not available.